Kaléo Announces License Agreement with Amgen for Auto-Injector Technology
Glen Allen, VA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Kaléo today announced that it has entered into a confidential license agreement with Amgen Inc. Under the terms of the agreement, Amgen obtained a license to certain of Kaléo's patented technology on auto-injectors. This agreement reflects Kaléo's innovative contribution to drug-device technologies and longstanding leadership in advancing patient-centric auto-injector solutions. Financial and other terms of the agreement were not disclosed.
About Kaléo
Kaléo is a pharmaceutical company and global leader in drug-delivery device technology and auto-injector innovation, providing millions of patients with security and peace of mind. Our patented Aerio™ platform, with unmatched capabilities and human factors engineering, powers our portfolio of auto-injector products, as well as products under development for third parties. Visit www.kaleo.com.
###
CC-US-0234
Carrie Siragusa Kaléo media.inquiries@kaleo.com
© Copyright Globe Newswire, Inc. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Globe Newswire, Inc.
